Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 379

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Stilgenbauer, Stephan, Bahlo, Jasmin, Schweighofer, Carmen D., Böttcher, Sebastian, Staib, Peter, Kiehl, Michael, Eckart, Michael J., Kranz, Gabriele, Goede, Valentin, Elter, Thomas, Bühler, Andreas, Winkler, Dirk, Kneba, Michael, Döhner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Wendtner, Clemens-Martin·2011·Journal of Clinical Oncology

Abstract

Purpose: The objective of this trial was to evaluate safety and efficacy of bendamustine combined with rituximab (BR) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Patients and Methods: Seventy-eight patients, including 22 patients with fludarabine-refractory disease (28.2%) and 14 patients (17.9%) with deletion of 17p, received BR chemoimmunotherapy. Bendamustine was administered at a dose of 70 mg/m 2 on days 1 and 2 combined with rituximab 375 mg/m 2 on day 0 of the first course and 500 mg/m 2 on day 1 during subsequent courses for up to six courses. Results: On the basis of intent-to-treat analysis, the overall response rate was 59.0% (95% CI, 47.3% to 70.0%). Complete response, partial response, and nodular partial response were achieved in 9.0%, 47.4%, and 2.6% of patients, respectively. Overall response rate was 45.5% in fludarabine-refractory patients and 60.5% in fludarabine-sensitive patients. Among genetic subgroups, 92.3% of patients with del(11q), 100% with trisomy 12, 7.1% with del(17p), and 58.7% with unmutated IGHV status responded to treatment. After a median follow-up time of 24 months, the median event-free survival was 14.7 months. Severe infections occurred in 12.8% of patients. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were documented in 23.1%, 28.2%, and 16.6% of patients, respectively. Conclusion: Chemoimmunotherapy with BR is effective and safe in patients with relapsed CLL and has notable activity in fludarabine-refractory disease. Major but tolerable toxicities were myelosuppression and infections. These promising results encouraged us to initiate a further phase II trial evaluating the BR regimen in patients with previously untreated CLL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.8061

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 379

Metadata

Authors
Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C. D., Böttcher, S., Staib, P., Kiehl, M., Eckart, M. J., Kranz, G., Goede, V., Elter, T., Bühler, A., Winkler, D., Kneba, M., Döhner, H., Eichhorst, B. F., Hallek, M., & Wendtner, C.-M.
Venue
Journal of Clinical Oncology
Published
2011-09-10
Volume
29
Issue
26
Pages
3559-3566
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2149515595
Cited by
379
References
22
FWCI
20.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. https://app.cochat.ai/papers/10.1200/jco.2010.33.8061
The paper
Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C. D., Böttcher, S., Staib, P., Kiehl, M., Eckart, M. J., Kranz, G., Goede, V., Elter, T., Bühler, A., Winkler, D., Kneba, M., Döhner, H., Eichhorst, B. F., Hallek, M., & Wendtner, C.-M. (2011). Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.8061

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.